论文部分内容阅读
目的观察罗格列酮对肝星状细胞增殖与Ⅰ型胶原合成的影响。方法采用HSC-T6肝星状细胞系,将培养的肝星状细胞(HSC)分为对照组、不同浓度的罗格列酮组(5、10、20μmol/L)。采用MTT法观察罗格列酮对HSC增殖的影响,采用ELISA法检测细胞培养液上清中Ⅰ型胶原的含量。结果与对照组相比,在10、20μmol/L罗格列酮组,罗格列酮可以抑制HSC的增殖(P<0.05),同时细胞培养液上清中I型胶原含量分别为135.72±6.00ng/ml、128.65±5.34ng/ml,均低于对照组(149.35±6.65ng/ml),差异有统计学意义(P<0.05)。结论罗格列酮可以抑制HSC的增殖,抑制肝星状细胞I型胶原的合成。
Objective To observe the effects of rosiglitazone on proliferation of hepatic stellate cells and type Ⅰ collagen synthesis. Methods The hepatic stellate cells (HSC) were divided into control group and rosiglitazone group (5, 10, 20μmol / L) by HSC-T6 hepatic stellate cell line. The effect of rosiglitazone on the proliferation of HSC was observed by MTT method. The content of type I collagen in the culture supernatant was detected by ELISA. Results Compared with the control group, rosiglitazone could inhibit the proliferation of HSC in 10 and 20μmol / L rosiglitazone group (P <0.05), and the content of type I collagen in the supernatant of cell culture medium was 135.72 ± 6.00 ng / ml, 128.65 ± 5.34ng / ml, all lower than the control group (149.35 ± 6.65ng / ml), the difference was statistically significant (P <0.05). Conclusion Rosiglitazone can inhibit the proliferation of HSC and inhibit the synthesis of type I collagen in hepatic stellate cells.